• Explore /
  • Poster
  • / A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).

A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).

Abstract Poster

Authors

Diwakar Davar

Diwakar Davar

UPMC Hillman Cancer Center, Pittsburgh, PA

Diwakar Davar , Alexandra Ikeguchi , Elizabeth Iannotti Buchbinder , Alexander Noor Shoushtari , Rino S. Seedor , Eric Bernicker , Sarah A. Weiss , Gregory A. Daniels , Timothy J. Panella , Hannah Frances Ryan , Howard Goodall , Ryan J. Sullivan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05549297

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS9594)

DOI

10.1200/JCO.2023.41.16_suppl.TPS9594

Abstract #

TPS9594

Poster Bd #

356a

Abstract Disclosures

Similar Posters

First Author: Paolo Antonio Ascierto

First Author: Marlana Orloff

First Author: Ahmad A. Tarhini

First Author: Charlee Nardin